SOUTH SAN FRANCISCO, Calif., July 17, 2026
IDEAYA Biosciences, Inc. has announced that it will present three clinical abstracts highlighting its darovasertib development program and one partner-led presentation featuring IDE849 at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 23–27 in Madrid, Spain. The presentations will showcase new data from multiple ongoing clinical studies evaluating darovasertib in uveal melanoma, including registrational and neoadjuvant trials, alongside updated Phase 1 clinical results for IDE849, a DLL3-targeting antibody-drug conjugate (ADC) being developed with Hengrui Pharma for small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). The scientific presentations reinforce IDEAYA’s expanding precision oncology pipeline and demonstrate continued progress toward developing targeted therapies for patients with difficult-to-treat cancers.
Darovasertib Clinical Program Advances Across Uveal Melanoma
At ESMO 2026, IDEAYA will present updated findings from three important clinical studies evaluating darovasertib, its investigational targeted therapy for uveal melanoma (UM). The presentations include follow-up data from the Phase 2 OptimUM-09 trial investigating neoadjuvant darovasertib in primary uveal melanoma, subgroup analyses from the registrational Phase 2/3 OptimUM-02 trial assessing darovasertib combined with crizotinib as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma, and updated results from the Phase 2 OptimUM-01 study in patients with HLA-A*02-positive metastatic uveal melanoma. Collectively, these studies are designed to evaluate the therapy across multiple stages of the disease while supporting its potential to become a new precision treatment option for patients with metastatic and localized uveal melanoma, an aggressive cancer with limited therapeutic alternatives.
IDE849 Expands Precision Oncology Pipeline in Lung Cancer
In addition to its proprietary clinical presentations, IDEAYA’s strategic partner Hengrui Pharma will present long-term Phase 1 clinical data for IDE849 (SHR-4849), an investigational DLL3-targeting topoisomerase I antibody-drug conjugate (ADC) developed for relapsed small cell lung carcinoma and other neuroendocrine carcinomas. The updated study results will evaluate the long-term safety profile and preliminary clinical activity of the novel ADC in patients with advanced cancers characterized by high DLL3 expression. IDEAYA noted that both monotherapy and combination therapy clinical studies are currently ongoing, while the program’s first registrational clinical trial is expected to begin by the end of the year through Hengrui Pharma in China and subsequently across additional regions, including the United States. The advancement of IDE849 strengthens IDEAYA’s growing portfolio of precision oncology therapeutics focused on genetically defined patient populations.
Advertisement
ESMO Presentations Highlight Broad Precision Medicine Strategy
The upcoming ESMO Congress represents an important scientific platform for IDEAYA to demonstrate the breadth of its precision medicine oncology pipeline, spanning targeted small molecules and next-generation antibody-drug conjugates (ADCs). The company’s research strategy combines translational biomarkers, structural biology, synthetic lethality, and precision drug discovery to develop therapies designed for molecularly selected cancer patients. By presenting updated clinical data across multiple tumor types and therapeutic modalities, IDEAYA continues to reinforce its commitment to advancing innovative treatments for cancers with significant unmet medical needs. Continued progress across the darovasertib and IDE849 programs may support future regulatory development while expanding precision treatment opportunities for patients with uveal melanoma, small cell lung cancer, and other aggressive malignancies where targeted therapeutic options remain limited.
Source: IDEAYA Biosciences press release
